Specialist Palliative Care and Potentially Avoidable Acute Care at the End of Life for Head and Neck Cancer in the Immunotherapy Era: Population‐Based Study

Rui Fu, Shiyu Sun, Khara Sauro, Andrea S. Fung, Frederick Dun‐Dery, Pin Cai, Andrew Fong, James A. King, Robyn Banerjee, Shamir P. Chandarana, T. Wayne Matthews, Joseph Dort, Aynharan Sinnarajah
Head and Neck · Wiley · 2026-11-16 · DOI: 10.1002/hed.70550

Аннотация

ABSTRACT Background The role of specialist palliative care (SPC) alongside immunotherapy in head and neck cancer (HNC) is unclear. Methods This retrospective population‐based cohort study included adults with HNC who died in 2013–2021 in Alberta, Canada. The primary exposure was SPC timing (early, late, none), with immunotherapy use in the last 12 months of life as a secondary exposure. The outcome was potentially avoidable acute care use (ICU admission, 15+ hospital days, or 2+ ED visits) in the last month of life. Multivariable logistic regression was performed. Results Of 1415 patients, 35.3%, 36.7%, and 28.0% received early, late, and no SPC, respectively, while 6.9% received immunotherapy. Early SPC was associated with 40% (95% CI 17%–57%) lower odds of potentially avoidable acute care use, while immunotherapy use was not associated with this outcome ( p ‐value = 0.91). Conclusion Early SPC was associated with lower potentially avoidable acute care use for HNC regardless of immunotherapy use.

Читать у издателя →

Похожие статьи